Measuring Exaptation and Its Impact on Innovation, Search, and Problem Solving

Published Online:https://doi.org/10.1287/orsc.2017.1116

References

  • Alexander K (1964) Notes on the Synthesis of Forms (Harvard University Press, Cambridge, MA).Google Scholar
  • Anderson C (2012) Makers: The New Industrial Revolution (Random House, New York).Google Scholar
  • Andriani P, Carignani G (2014) Modular exaptation: A missing link in the synthesis of artificial forms. Res. Policy 43(8):1608–1620.CrossrefGoogle Scholar
  • Andriani P, Carignani G (2017) Complex analogy and modular exaptation: Some definitional issues. Mitleton-Kelly E, Paraskevas A, Day C, eds. Handbook of Research Methods in Complexity Science (Edward Elgar, Cheltenham, UK). Forthcoming.Google Scholar
  • Andriani P, Cohen J (2013) From exaptation to radical niche construction in biological and technological complex systems. Complexity 18(5):7–14.CrossrefGoogle Scholar
  • Anonymous (2012) The Global Use of Medicines: Outlook Through 2016 (IMS Institute for Healthcare Informatics, Parsippany, NJ).Google Scholar
  • Arthur BA (2009) The Nature of Technology: What Is and How It Evolves (Penguin Books, London).Google Scholar
  • Baldwin C, von Hippel E (2011) Modeling a paradigm shift: From producer innovation to user and open collaborative innovation. Organ. Sci. 22(6):1399–1417.LinkGoogle Scholar
  • Ban TA (2006) The role of serendipity in drug discovery. Dialogues Clinical Neuroscience 8(3):335–344.Google Scholar
  • Barczak G, Griffin A, Kahn K (2009) Perspective: Trends and drivers of success in NPD practices: Results of the 2003 PDMA best practices study. J. Product Innovation Management 26(1):3–23.CrossrefGoogle Scholar
  • Bonaccorsi A (2011) A functional theory of technology and technological change. Antonelli C, ed. Handbook on the Economic Complexity of Technological Change (Edward Elgar, Cheltenham, UK), 286–337.CrossrefGoogle Scholar
  • Buderi R (1997) The Invention That Changed the World (Simon & Schuster, New York).Google Scholar
  • Cattani G (2005) Preadaptation, firm heterogeneity, and technological performance: A study on the evolution of fiber optics, 1970–1995. Organ. Sci. 16(6):563–580.LinkGoogle Scholar
  • Cattani G (2006) Technological pre-adaptation, speciation, and emergence of new technologies: How Corning invented and developed fiber optics. Indust. Corporate Change 15(2):285–318.CrossrefGoogle Scholar
  • Ching K (2016) Exaptation dynamics and entrepreneurial performance: Evidence from the internet video industry. Indust. Corporate Change 25(1):181–198.CrossrefGoogle Scholar
  • Chouduri SP, Van Alstine MW, Parker GG (2016) Platform Revolution (Norton & Company, New York).Google Scholar
  • Clauset A, Shalizi CR, Newman MEJ (2009) Power-law distributions in empirical data. Soc. Indust. Appl. Math. Rev. 51(4):661–703.CrossrefGoogle Scholar
  • Cohen MD, March JG, Olsen JP (1972) A garbage can model of organizational choice. Admin. Sci. Quart. 17(1):1–25.CrossrefGoogle Scholar
  • Comroe Jr JH (1977) Roast pig and scientific discovery. Part I. Amer. Rev. Respiratory Disease 115(5):853–860.Google Scholar
  • Dawkins R (1986) The Blind Watchmaker (W. W. Norton, New York).Google Scholar
  • DeMonaco HJ, Ali A, Von Hippel E (2006) The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy 26(3):323–332.CrossrefGoogle Scholar
  • Dew N (2009) Serendipity in entrepreneurship. Organ. Stud. 30(7):735–753.CrossrefGoogle Scholar
  • Dew N, Sarasvathy SD (2016) Exaptation and niche construction: Behavioral Insights for an evolutionary theory. Indust. Corporate Change 25(1):167–179.CrossrefGoogle Scholar
  • Dew N, Sarasvathy SD, Venkataraman S (2004) The economic implications of exaptation. J. Evolutionary Econom. 14(1):69–84.CrossrefGoogle Scholar
  • Dew N, Read S, Sarasvathy SD, Wiltbank R (2008) Outlines of a behavioral theory of the entrepreneurial firm. J. Econom. Behav. Organ. 66(1):37–59.CrossrefGoogle Scholar
  • Dudley J, Deshpande T, Butte A (2011) Exploiting drug–disease relationships for computational drug repositioning. Briefings Bioinformatics 12(4):303–311.CrossrefGoogle Scholar
  • Felin T, Zenger T (2016) Strategy, problems, and a theory for the firm. Organ. Sci. 27(1):221–231.Google Scholar
  • Felin T, Kauffman S, Koppl R, Longo G (2014) Economic opportunity and evolution: beyond landscapes and bounded rationality. Strategic Entrepreneurship J. 8(4):269–282.CrossrefGoogle Scholar
  • Felin T, Kauffman SA, Mastrogiorgio A, Mastrogiorgio M (2016) Factor markets, actors and affordances. Indust. Corporate Change 25(1):133–147.CrossrefGoogle Scholar
  • Fleming A (1929) On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. British J. Experiment. Pathology 10(3):226–236.Google Scholar
  • Garcia R, Calantone R (2002) A critical look at technological innovation typology and innovativeness terminology: A literature review. J. Product Innovation Management 19(2):110–132.CrossrefGoogle Scholar
  • Garud R, Nayyar P, Shapira Z (1997) Technological Innovation: Oversights and Foresights (Cambridge University Press, Cambridge, MA).CrossrefGoogle Scholar
  • Gavetti G (2012) PERSPECTIVE—Toward a behavioral theory of strategy. Organ. Sci. 23(1):267–285.LinkGoogle Scholar
  • Gavetti G, Levinthal DA, Rivkin JW (2005) Strategy making in novel and complex worlds: The power of analogy. Strategic Management J. 26(8):691–712.CrossrefGoogle Scholar
  • Gelijns A (1998) Capturing the unexpected benefits of medical research. New England J. Medicine 339(10):693–698.CrossrefGoogle Scholar
  • Gentner D (1983) Structure-mapping: A theoretical framework for analogy. Cognitive Sci. 7(2):155–170.CrossrefGoogle Scholar
  • Gibson J (1986) The Ecological Approach to Visual Perception: Classic Edition (Taylor & Francis, Oxford, UK).Google Scholar
  • Gould SJ (2002) The Structure of Evolutionary Theory (Harvard University Press, Boston).CrossrefGoogle Scholar
  • Gould S, Vrba E (1982) Exaptation—A missing term in the science of form. Paleobiology 8(1):4–15.CrossrefGoogle Scholar
  • Gundling E (2000) The 3M Way to Innovation: Balancing People and Profit (Kodansha International, Tokyo).Google Scholar
  • Infield GB (1976) Disaster at Bari (New English Library, London).Google Scholar
  • Kauffman S (2000) Investigations (Oxford University Press, Oxford, UK).CrossrefGoogle Scholar
  • Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. British J. Dermatology. 108(4):461–466.CrossrefGoogle Scholar
  • Kragh H (2008) From disulfiram to antabuse: The invention of a drug. Bull. Hist. Chemistry 33(2):82–88.Google Scholar
  • Latour B (2005) Reassembling the Social: An Introduction to Actor-Network-Theory (Oxford University Press, Oxford, UK).CrossrefGoogle Scholar
  • Levinthal D (1998) The slow pace of rapid technological change: Gradualism and punctuation in technological change. Indust. Corporate Change 7(2):217–247.CrossrefGoogle Scholar
  • Li JJ (2006) Laughing Gas, Viagra end Libitor: The Human Stories Behind the Drugs We Use (Oxford University Press, Oxford, UK).Google Scholar
  • Loe M (2004) The Rise of Viagra: How the Little Blue Pill Changed Sex in America (New York University Press, New York).Google Scholar
  • Longo G, Montevil M, Kauffman S (2012) No entailing laws, but enablement in the evolution of the biosphere. Proc. 14th Internat. Conf. Genetic Evolutionary Comput. Conf. Companion, July 7–11, Philadelphia, 1379–1392.CrossrefGoogle Scholar
  • Mastrogiorgio M, Gilsing V (2016) Innovation through exaptation and its determinants: The role of technological complexity, analogy making, and patent scope. Res. Policy 45(7):1419–1435.CrossrefGoogle Scholar
  • Maxwell RA, Eckardt SB (1990) Chlorpromazine. Maxwell RA, Eckardt SB, eds. Drug Discovery: A Casebook and Analysis (Springer, New York), 111–122.CrossrefGoogle Scholar
  • Meyers MA (2007) Happy Accidents: Serendipity in Major Medical Breakthroughs in the Twentieth Century (Arcade, New York).Google Scholar
  • Mintzberg H, Waters J (1985) Of strategies, deliberate and emergent. Strategic Management J. 6(3):257–262.CrossrefGoogle Scholar
  • Mukherjee S (2010) The Emperor of All Maladies: A Biography of Cancer (Simon and Schuster, New York).Google Scholar
  • Mukhurjee S (2012) Post-Prozac nation: The science and history of treating depression. New York Times (April 19), http://www.nytimes.com/2012/04/22/magazine/the-science-and-history-of-treating-depression.html.Google Scholar
  • Nebeker F (2009) Dawn of the Electronic Age: Electrical Technologies in the Shaping of the Modern World, 1914 to 1945 (John Wiley, New York).CrossrefGoogle Scholar
  • Nerkar A, Roberts PW (2004) Technological and product-market experience and the success of new product introductions in the pharmaceutical industry. Strategic Management J. 25(8–9):779–799.CrossrefGoogle Scholar
  • Osepchuk JM (1984) A history of microwave heating applications. IEEE Trans Microwave Theory Techniques 32(9):1200–1224.CrossrefGoogle Scholar
  • Page S (2008) The Difference (Princeton University Press, Princeton, NJ).Google Scholar
  • Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch. Internal Medicine 166(9):1021–1026.CrossrefGoogle Scholar
  • Read S, Sarasvathy S, Dew N, Wiltbank R, Ohlsson A (2010) Effectual Entrepreneurship (Taylor & Francis, Oxford, UK).Google Scholar
  • Rehman W, Arfons L, Lazarus H (2011) The rise, fall and subsequent triumph of thalidomide. Therapeutic Advances Hematology 2(5):291–308.CrossrefGoogle Scholar
  • Roin BN (2014) Solving the problem of new uses. Working paper, Massachusetts Institute of Technology, Cambridge, MA.Google Scholar
  • Schirmer R, Adlera M, Pickhardt M, Mandelkow E (2011) “Lest we forget you—Methylene blue….” Neurobiology Aging 32(2325): 2325.e7–2325.e16.CrossrefGoogle Scholar
  • Schön DA (1983) The Reflective Practitioner? How Professionals Think in Action (Basic Books, New York).Google Scholar
  • Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clinical Pharmacology Therapeutics 6(3):303–306.CrossrefGoogle Scholar
  • Stephens TD, Brynner R (2009) Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine (Basic Books, New York).Google Scholar
  • Taleb N (2012) Anti-Fragile: How to Live in a World We Don’t Understand (Allen Lane, London).Google Scholar
  • Terwiesch C, Ulrich KT (2009) Innovation Tournaments (Harvard Business Press, Cambridge, MA).Google Scholar
  • Tillman K, Burton B, Jacques LB, Phurrough SE (2009) Compendia and anticancer therapy under Medicare. Ann. Internal Medicine 150(5):348–350.CrossrefGoogle Scholar
  • Tone A (2008) The Age of Anxiety: A History of America’s Turbulent Affair with Tranquilizers (Basic Books, New York).Google Scholar
  • Topaz M, Shafran-Topaz L, Bowles KH (2013) ICD-9 to ICD-10: evolution, revolution, and current debates in the United States. Perspect. Health Inform. Management 10(Spring):1–8.Google Scholar
  • Vallery-Radot R (1902) The Life of Pasteur (McClure, Phillips and Co., New York).Google Scholar
  • Van de Ven AH, Polley DE, Garud R, Venkataraman S (1999) The Innovation Journey (Oxford University Press, Oxford, UK).Google Scholar
  • Ventola CL (2009) Off-label drug information: Regulation, distribution, evaluation, and related controversies. P T 34(8):428–440.Google Scholar
  • von Hippel E (2005) Democratizing Innovation (MIT Press, Cambridge, MA).CrossrefGoogle Scholar
  • von Hippel E, von Krogh G (2016) Identifying viable “need–solution pairs”: Problem solving without problem formulation. Organ. Sci. 27(1):207–221.LinkGoogle Scholar
  • von Hippel EA, DeMonaco HJ, de Jong JPJ (2016) Market failure in the diffusion of user innovations: The case of “off-label” innovations by medical clinicians. Working paper, Massachusetts Institute of Technology, Cambridge, MA.Google Scholar
  • Wagner A (2011) The Origins of Evolutionary Innovations (Oxford University Press, Oxford, UK).CrossrefGoogle Scholar
  • Wiener N (1993) Invention: The Care and Feeding of Ideas (MIT Press, Cambridge, MA).Google Scholar
  • Winter S (2012) Purpose and progress in the theory of strategy: Comments on Gavetti. Organ. Sci. 23(1):288–297.LinkGoogle Scholar
  • Woolf S (2008) The meaning of translational research and why it matters. Jama 299(2):211–213.CrossrefGoogle Scholar
INFORMS site uses cookies to store information on your computer. Some are essential to make our site work; Others help us improve the user experience. By using this site, you consent to the placement of these cookies. Please read our Privacy Statement to learn more.